^Allschwil, Switzerland - June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, will be presented as an oral presentation by Prof. M.
newratings de newratings.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newratings.de Daily Mail and Mail on Sunday newspapers.
Idorsia Pharmaceuticals Ltd: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Allschwil, Switzerland – June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the
New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.